Use of Sorafenib in Advanced HCC Patients with Child-Pugh Class B Liver Dysfunction

    loading  Checking for direct PDF access through Ovid



Early pivotal trials demonstrating the efficacy of sorafenib for patients with advanced hepatocellular cancer included primarily those with minimal liver dysfunction (Child-Pugh [CP] class A). The current Phase 2 study examined sorafenib treatment in both CP class A and B patients. Those with CP class B liver dysfunction were shown to tolerate sorafenib but treatment outcomes remained less satisfactory than for CP class A patients.


Pressiani T, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: A prospective feasibility analysis. Ann Oncol 2013;24:406-411.

Related Topics

    loading  Loading Related Articles